Cantor Fitzgerald Reiterates Neutral Rating on ADMA Biologics, Inc. (ADMA)

Market Context

ADMA Biologics, Inc. operates in the Healthcare sector. The stock currently trades at $13.21 with a market capitalization of $3.7B. The stock has declined 31.8% over the past 52 weeks.

Analyst coverage from Cantor Fitzgerald provides professional research and price targets that many institutional investors reference when making allocation decisions. The consensus of analyst opinions — along with the range of price targets — helps frame market expectations for ADMA Biologics, Inc.

Analyst ratings and price targets are one input among many for investment decisions. Historical studies show that consensus analyst recommendations have mixed predictive power on their own, but significant changes in consensus — such as multiple upgrades or downgrades in a short period — can be more meaningful signals.

Recent Analyst Activity for ADMA Biologics, Inc.

Among the 10 most recent ratings: 8 Buy, 2 Hold, 0 Sell.

Date	Firm	Rating	Price Target
Nov 05, 2026	Cantor Fitzgerald	Neutral	N/A
Jul 15, 2026	Mizuho	Outperform	N/A
May 07, 2026	Canaccord Genuity	Buy	N/A
May 07, 2026	Mizuho	Outperform	N/A
Apr 21, 2026	Canaccord Genuity	Buy	N/A

Related Tools: Analyst Ratings Dashboard | View ADMA Stock Page